Compare Smith & Nephew plc (SNN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs NEOS S&P 500 High Income ETF — how do they compare? Smith & Nephew plc trades at $27.17 (market cap $11.10B), while NEOS S&P 500 High Income ETF trades at $53.97 (market cap $12.50B). The key difference: Smith & Nephew plc and NEOS S&P 500 High Income ETF are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| SNN | SPYI | |
|---|---|---|
Market Cap | $11.10B | $12.50B |
Volume | 1,051,703 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $37.17 | $54.42 |
52-Week Low | $26.42 | $47.98 |
Typical Hold Time | 120 Days | 57 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
SPYI trades at $54.01, down 0.13% with a bullish technical outlook from moving averages but neutral oscillators. The ETF maintains consistent monthly dividend distributions around $0.53-$0.54, though recent analysis highlights concerns about principal erosion from covered call strategies. Media coverage focuses heavily on retirement income strategies and the trade-offs between high yields and capital preservation.
The outlook remains cautious as SPYI faces scrutiny over whether its high income distributions come at the expense of long-term capital growth. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of covered call returns and sequence risk for retirees present significant headwinds for investors seeking both income and principal protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
